Can-Fite completes dosing in interim-analysis cohort of Phase III psoriasis trial
CANF•Can-Fite completed dosing in the first 247 patients in its Phase III piclidenoson trial for moderate-to-severe plaque psoriasis, with interim efficacy and safety results expected in the first quarter of 2027.
1. Interim analysis cohort
Can-Fite completed dosing in the first 247 patients in its pivotal, placebo-controlled Phase III trial of oral piclidenoson for moderate-to-severe plaque psoriasis. Interim efficacy and safety results are expected in the first quarter of 2027, following review by an independent monitoring committee. The trial is being conducted under a protocol agreed with the FDA and European Medicines Agency.




